Denali Therapeutics Inc. (DNLI)
NASDAQ: DNLI · Real-Time Price · USD
21.45
-0.04 (-0.19%)
Dec 20, 2024, 4:00 PM EST - Market closed
Denali Therapeutics Revenue
In the year 2023, Denali Therapeutics had annual revenue of $330.53M with 204.74% growth.
Revenue (ttm)
$330.53M
Revenue Growth
+204.74%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
445
Market Cap
3.09B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 330.53M | 222.07M | 204.74% |
| Dec 31, 2022 | 108.46M | 59.80M | 122.90% |
| Dec 31, 2021 | 48.66M | -287.00M | -85.50% |
| Dec 31, 2020 | 335.66M | 308.98M | 1,158.19% |
| Dec 31, 2019 | 26.68M | -102.48M | -79.35% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BrightSpring Health Services | 10.59B |
| QuidelOrtho | 2.82B |
| Envista Holdings | 2.50B |
| Warby Parker | 742.53M |
| NovoCure | 577.74M |
| Inari Medical | 574.50M |
| Veracyte | 425.33M |
| Janux Therapeutics | 13.05M |
DNLI News
- 5 weeks ago - Denali Has A Neurodegenerative Edge Despite Market Skepticism - Seeking Alpha
- 6 weeks ago - Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights - GlobeNewsWire
- 3 months ago - Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome) - GlobeNewsWire
- 4 months ago - Denali Therapeutics: A Promising Biotech With Revolutionary BBB-Crossing Technology - Seeking Alpha
- 4 months ago - Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following Intravenous Administration - GlobeNewsWire
- 5 months ago - Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights - GlobeNewsWire
- 7 months ago - Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies - GlobeNewsWire
- 7 months ago - Denali Therapeutics: MPS Treatment Program Continues With End Of 2024 Data - Seeking Alpha